STERIS (STE) Stock Forecast, Price Target & Predictions
STE Stock Forecast
STERIS stock forecast is as follows: an average price target of $256.67 (represents a 13.98% upside from STE’s last price of $225.18) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
STE Price Target
STE Analyst Ratings
STERIS Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 24, 2024 | Jason Bednar | Piper Sandler | $260.00 | $221.15 | 17.57% | 15.46% |
Sep 03, 2024 | Brett Fishbin | KeyBanc | $265.00 | $241.10 | 9.91% | 17.68% |
May 10, 2024 | Jason Bednar | Piper Sandler | $225.00 | $225.94 | -0.42% | -0.08% |
Apr 04, 2024 | Mike Polark | Wolfe Research | $245.00 | $216.65 | 13.09% | 8.80% |
STERIS Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 2 | 4 |
Avg Price Target | $260.00 | $262.50 | $248.75 |
Last Closing Price | $225.18 | $225.18 | $225.18 |
Upside/Downside | 15.46% | 16.57% | 10.47% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 24, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
Oct 24, 2024 | Piper Sandler | Underperform | Underperform | Hold |
Oct 24, 2024 | Piper Sandler | Neutral | Overweight | Upgrade |
Sep 03, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
Sep 03, 2024 | JMP Securities | Underperform | Underperform | Hold |
Sep 03, 2024 | KeyBanc | Overweight | Overweight | Hold |
Aug 07, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
Jun 10, 2024 | Piper Sandler | Neutral | Neutral | Hold |
May 10, 2024 | Piper Sandler | Neutral | Neutral | Hold |
Apr 04, 2024 | Wolfe Research | Outperform | Outperform | Hold |
STERIS Financial Forecast
STERIS Revenue Forecast
Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.40B | $1.34B | $1.28B | $1.38B | $1.22B | $1.20B | $1.16B | $1.21B | $968.42M | $1.20B | $1.21B | $873.53M | $668.93M | $756.13M | $808.92M | $822.99M | $696.80M |
Avg Forecast | $1.69B | $1.56B | $1.50B | $1.44B | $1.58B | $1.46B | $1.41B | $1.36B | $1.50B | $1.38B | $1.33B | $1.27B | $1.41B | $1.35B | $1.30B | $1.21B | $1.27B | $1.27B | $1.22B | $1.22B | $1.17B | $1.19B | $1.15B | $904.86M | $876.22M | $793.03M | $719.54M | $643.38M | $799.57M | $748.45M |
High Forecast | $1.69B | $1.56B | $1.50B | $1.44B | $1.58B | $1.46B | $1.41B | $1.36B | $1.50B | $1.38B | $1.35B | $1.27B | $1.41B | $1.36B | $1.31B | $1.21B | $1.27B | $1.27B | $1.22B | $1.22B | $1.17B | $1.19B | $1.15B | $904.86M | $876.22M | $793.03M | $719.54M | $643.38M | $799.57M | $748.45M |
Low Forecast | $1.69B | $1.56B | $1.50B | $1.44B | $1.58B | $1.46B | $1.41B | $1.36B | $1.50B | $1.38B | $1.31B | $1.27B | $1.41B | $1.34B | $1.28B | $1.21B | $1.27B | $1.27B | $1.22B | $1.22B | $1.17B | $1.19B | $1.15B | $904.86M | $876.22M | $793.03M | $719.54M | $643.38M | $799.57M | $748.45M |
# Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% | 1.06% | 1.09% | 0.96% | 0.98% | 0.95% | 1.03% | 0.81% | 1.04% | 1.34% | 1.00% | 0.84% | 1.05% | 1.26% | 1.03% | 0.93% |
STERIS EBITDA Forecast
Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $216.16M | $185.86M | $188.92M | $226.12M | $190.88M | $318.09M | $158.45M | $91.92M | $76.47M | $230.90M | $322.78M | $203.66M | $165.41M | $196.79M | $205.17M | $208.54M | $158.58M |
Avg Forecast | $332.28M | $306.34M | $295.60M | $282.48M | $311.43M | $287.85M | $277.82M | $267.45M | $294.63M | $271.14M | $261.67M | $250.28M | $344.19M | $265.25M | $255.54M | $237.49M | $312.90M | $527.34M | $240.36M | $240.60M | $284.45M | $234.89M | $226.54M | $177.97M | $224.86M | $155.98M | $141.52M | $126.54M | $200.70M | $147.21M |
High Forecast | $332.28M | $306.34M | $295.60M | $282.48M | $311.43M | $287.85M | $277.82M | $267.45M | $294.63M | $271.14M | $265.57M | $250.28M | $413.03M | $267.23M | $258.37M | $237.49M | $375.48M | $632.80M | $240.36M | $240.60M | $341.34M | $234.89M | $226.54M | $177.97M | $269.84M | $155.98M | $141.52M | $126.54M | $240.85M | $147.21M |
Low Forecast | $332.28M | $306.34M | $295.60M | $282.48M | $311.43M | $287.85M | $277.82M | $267.45M | $294.63M | $271.14M | $257.76M | $250.28M | $275.35M | $263.27M | $252.28M | $237.49M | $250.32M | $421.87M | $240.36M | $240.60M | $227.56M | $234.89M | $226.54M | $177.97M | $179.89M | $155.98M | $141.52M | $126.54M | $160.56M | $147.21M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.73% | 0.80% | 0.72% | 0.36% | 1.32% | 0.66% | 0.32% | 0.33% | 1.02% | 1.81% | 0.91% | 1.06% | 1.39% | 1.62% | 1.04% | 1.08% |
STERIS Net Income Forecast
Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $140.74M | $115.32M | $123.55M | $187.22M | $123.83M | $-315.23M | $111.26M | $52.26M | $-21.90M | $69.81M | $-21.81M | $88.85M | $88.12M | $105.86M | $88.19M | $123.32M | $104.93M |
Avg Forecast | $314.88M | $278.17M | $262.52M | $243.78M | $286.87M | $252.08M | $235.69M | $226.91M | $263.77M | $231.83M | $210.96M | $196.48M | $147.46M | $215.50M | $199.08M | $184.84M | $134.05M | $144.21M | $197.10M | $190.31M | $121.87M | $194.98M | $180.86M | $148.27M | $96.34M | $150.89M | $125.88M | $97.19M | $118.63M | $141.11M |
High Forecast | $314.88M | $278.17M | $262.52M | $243.78M | $286.87M | $252.08M | $235.69M | $226.91M | $263.77M | $231.83M | $215.96M | $196.49M | $176.95M | $217.50M | $205.03M | $184.84M | $160.87M | $173.05M | $197.10M | $190.31M | $146.24M | $198.48M | $180.86M | $148.27M | $115.61M | $150.89M | $125.88M | $97.19M | $142.36M | $141.11M |
Low Forecast | $314.88M | $278.17M | $262.52M | $243.78M | $286.87M | $252.08M | $235.69M | $226.91M | $263.77M | $231.83M | $205.96M | $196.47M | $117.97M | $214.51M | $188.19M | $184.84M | $107.24M | $115.37M | $197.10M | $190.31M | $97.49M | $191.47M | $180.86M | $148.27M | $77.07M | $150.89M | $125.88M | $97.19M | $94.91M | $141.11M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.58% | 0.67% | 1.40% | 0.86% | -1.60% | 0.58% | 0.43% | -0.11% | 0.39% | -0.15% | 0.92% | 0.58% | 0.84% | 0.91% | 1.04% | 0.74% |
STERIS SG&A Forecast
Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $360.52M | $380.65M | $359.06M | $335.91M | $305.14M | $323.19M | $334.63M | $453.64M | $393.75M | $344.80M | $310.56M | $221.07M | $155.17M | $172.71M | $182.37M | $189.06M | $178.78M |
Avg Forecast | $439.21M | $404.93M | $390.74M | $373.39M | $411.65M | $380.49M | $367.22M | $353.52M | $389.44M | $358.39M | $345.88M | $330.83M | $366.90M | $350.61M | $337.79M | $313.92M | $333.54M | $311.84M | $317.71M | $318.04M | $303.22M | $310.48M | $299.44M | $235.25M | $239.70M | $206.18M | $187.07M | $167.27M | $181.88M | $194.58M |
High Forecast | $439.21M | $404.93M | $390.74M | $373.39M | $411.65M | $380.49M | $367.22M | $353.52M | $389.44M | $358.39M | $351.04M | $330.83M | $440.28M | $353.23M | $341.52M | $313.92M | $400.25M | $374.21M | $317.71M | $318.04M | $363.86M | $310.48M | $299.44M | $235.25M | $287.64M | $206.18M | $187.07M | $167.27M | $218.26M | $194.58M |
Low Forecast | $439.21M | $404.93M | $390.74M | $373.39M | $411.65M | $380.49M | $367.22M | $353.52M | $389.44M | $358.39M | $340.72M | $330.83M | $293.52M | $347.99M | $333.46M | $313.92M | $266.83M | $249.47M | $317.71M | $318.04M | $242.58M | $310.48M | $299.44M | $235.25M | $191.76M | $206.18M | $187.07M | $167.27M | $145.51M | $194.58M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.13% | 1.14% | 1.01% | 0.98% | 1.02% | 1.05% | 1.50% | 1.27% | 1.15% | 1.32% | 0.92% | 0.75% | 0.92% | 1.09% | 1.04% | 0.92% |
STERIS EPS Forecast
Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.42 | $1.17 | $1.25 | $1.89 | $1.24 | $-3.15 | $1.11 | $0.52 | $-0.24 | $0.70 | $1.43 | $1.02 | $1.04 | $1.24 | $1.34 | $1.45 | $1.00 |
Avg Forecast | $3.17 | $2.80 | $2.64 | $2.45 | $2.89 | $2.54 | $2.37 | $2.28 | $2.65 | $2.33 | $2.12 | $1.98 | $2.35 | $2.17 | $2.00 | $1.86 | $2.15 | $2.19 | $1.98 | $1.92 | $2.02 | $1.96 | $1.82 | $1.49 | $1.77 | $1.52 | $1.27 | $0.98 | $1.57 | $1.42 |
High Forecast | $3.17 | $2.80 | $2.64 | $2.45 | $2.89 | $2.54 | $2.37 | $2.28 | $2.65 | $2.33 | $2.17 | $1.98 | $2.35 | $2.19 | $2.06 | $1.86 | $2.15 | $2.19 | $1.98 | $1.92 | $2.02 | $2.00 | $1.82 | $1.49 | $1.77 | $1.52 | $1.27 | $0.98 | $1.57 | $1.42 |
Low Forecast | $3.17 | $2.80 | $2.64 | $2.45 | $2.89 | $2.54 | $2.37 | $2.28 | $2.65 | $2.33 | $2.07 | $1.98 | $2.35 | $2.16 | $1.89 | $1.86 | $2.15 | $2.19 | $1.98 | $1.92 | $2.02 | $1.93 | $1.82 | $1.49 | $1.77 | $1.52 | $1.27 | $0.98 | $1.57 | $1.42 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.58% | 0.67% | 0.88% | 0.57% | -1.59% | 0.58% | 0.26% | -0.12% | 0.38% | 0.96% | 0.57% | 0.68% | 0.98% | 1.37% | 0.92% | 0.70% |
STERIS Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
OFIX | Orthofix Medical | $16.96 | $31.00 | 82.78% | - |
IRTC | iRhythm | $75.04 | $121.17 | 61.47% | Buy |
LIVN | LivaNova | $51.13 | $70.50 | 37.88% | Buy |
CNMD | CONMED | $70.40 | $96.00 | 36.36% | Buy |
BRKR | Bruker | $59.29 | $73.75 | 24.39% | Buy |
PODD | Insulet | $235.61 | $270.93 | 14.99% | Buy |
STE | STERIS | $225.18 | $256.67 | 13.98% | Buy |
MASI | Masimo | $144.22 | $160.20 | 11.08% | Buy |
ITGR | Integer | $126.45 | $138.00 | 9.13% | Buy |
ZIMV | ZimVie | $14.04 | $14.50 | 3.28% | Buy |
PEN | Penumbra | $233.30 | $224.85 | -3.62% | Buy |
GKOS | Glaukos | $131.77 | $119.33 | -9.44% | Buy |
SYK | Stryker | $367.15 | $317.96 | -13.40% | Buy |
STE Forecast FAQ
Is STERIS a good buy?
Yes, according to 4 Wall Street analysts, STERIS (STE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of STE's total ratings.
What is STE's price target?
STERIS (STE) average price target is $256.67 with a range of $245 to $265, implying a 13.98% from its last price of $225.18. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will STERIS stock go up soon?
According to Wall Street analysts' prediction for STE stock, the company can go up by 13.98% (from the last price of $225.18 to the average price target of $256.67), up by 17.68% based on the highest stock price target, and up by 8.80% based on the lowest stock price target.
Can STERIS stock reach $300?
STE's average twelve months analyst stock price target of $256.67 does not support the claim that STERIS can reach $300 in the near future.
What is STERIS's current price target trend?
1 Wall Street analyst forecast a $260 price target for STERIS (STE) this month, up 15.46% from its last price of $225.18. Compared to the last 3 and 12 months, the average price target increased by 16.57% and increased by 10.47%, respectively.
What are STERIS's analysts' financial forecasts?
STERIS's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $5.82B (high $5.82B, low $5.82B), average EBITDA is $1.14B (high $1.14B, low $1.14B), average net income is $1B (high $1B, low $1B), average SG&A $1.51B (high $1.51B, low $1.51B), and average EPS is $10.08 (high $10.08, low $10.08). STE's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $6.19B (high $6.19B, low $6.19B), average EBITDA is $1.22B (high $1.22B, low $1.22B), average net income is $1.1B (high $1.1B, low $1.1B), average SG&A $1.61B (high $1.61B, low $1.61B), and average EPS is $11.06 (high $11.06, low $11.06).
Did the STE's actual financial results beat the analysts' financial forecasts?
Based on STERIS's last annual report (Mar 2023), the company's revenue was $4.96B, which missed the average analysts forecast of $4.99B by -0.66%. Apple's EBITDA was $1.25B, missing the average prediction of $1.32B by -5.37%. The company's net income was $107.03M, missing the average estimation of $665.67M by -83.92%. Apple's SG&A was $1.3B, beating the average forecast of $1.28B by 1.39%. Lastly, the company's EPS was $1.07, missing the average prediction of $8.24 by -87.01%. In terms of the last quarterly report (Dec 2023), STERIS's revenue was $1.4B, beating the average analysts' forecast of $1.35B by 3.49%. The company's EBITDA was $216.16M, missing the average prediction of $265.25M by -18.51%. STERIS's net income was $140.74M, missing the average estimation of $215.5M by -34.69%. The company's SG&A was $360.52M, beating the average forecast of $350.61M by 2.83%. Lastly, the company's EPS was $1.42, missing the average prediction of $2.17 by -34.52%